1
|
NIE W, Li M, Liu B, Wang J, Jin L, Zhang Y, Ni A, Xiao L, Shen X, Chen J, Lin W, Han F. POS-385 CIRCPTPN14 BINDS TO FUBP1 TO PROMOTE TRANSCRIPTION OF C-MYC IN KIDNEY FIBROSIS. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
2
|
Dang Y, van Heusden C, Gentzsch M, Steward I, Hickey A, Ni A, Rudolph J, Kreda S. 598: Correction of CF splicing mutations with oligonucleotides. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)02021-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Hao G, Ni A, Chang YJ, Hall K, Lee SH, Chiu HT, Yang SF, Sheu KL, Chen SC. Improve the clinical effective decision of the oral feeding readiness in preterm infants: Revise and validate the TC-POFRAS. J Neonatal Perinatal Med 2021; 15:317-325. [PMID: 34719446 DOI: 10.3233/npm-210869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Currently there is limited information to guide health professionals regarding the optimal time frame to initiate safe and effective oral feedings to preterm infants. The study aims to revise and validate a streamlined version of the Traditional Chinese-Preterm Oral Feeding Readiness Assessment Scale, the TC-POFRAS®, and evaluate its construct validity in the clinical decisions regarding feeding readiness of preterm infants. METHODS Eighty-one clinically stable preterm infants were assessed using the TC-POFRAS for oral feeding readiness. Item-total correlation analysis was used to check if any item was inconsistent with the averaged TC-POFRAS scores. Cronbach's α coefficient was used to evaluate the inter-item consistency. Exploratory factor analysis was used to determine the coherence of variables to reorganize assessment domains. The revised version of TC-POFRAS (TC-POFRAS®) was developed and a new cut-off score based on discriminant accuracy was established. RESULTS Based on the results from statistical analysis, five items ("lips posture," "tongue posture," "biting reflex," "gag reflex," and "tongue cupping") were deleted from the original TC-POFRAS to form the TC-POFRAS®. The TC-POFRAS®'s global accuracy was 92.1%. The cut-off value of 19 was the one that presented the most optimization of sensitivity based on specificity. The TC-POFRAS® was reconstructed into corrected gestational age and five behavioral domains. CONCLUSIONS The TC-POFRAS® is considered a valid, safe, and accurate objective instrument to assist health professionals to initiate oral feeding of preterm infants.
Collapse
Affiliation(s)
- G Hao
- Department of Communication Sciences and Disorders, College of Health and Sciences, North Carolina Central University, NC, USA
| | - A Ni
- Department of Communication Sciences and Disorders, College of Health and Sciences, North Carolina Central University, NC, USA
| | - Y J Chang
- Department of Speech Language Pathology and Audiology, Chung Shan Medical University, Taichung, Taiwan, ROC.,Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC
| | - K Hall
- Department of Communication Sciences and Disorders, College of Health and Sciences, North Carolina Central University, NC, USA
| | - S H Lee
- School of Nursing, Chung Shan Medical University, Taichung, Taiwan, ROC
| | - H T Chiu
- Neonatal Intensive Care Unit, Chung Shan Medical University, Taichung, Taiwan, ROC
| | - S F Yang
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC
| | - K L Sheu
- Department of Family and Community Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC.,School of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC
| | - S C Chen
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC.,Department of Family and Community Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC.,School of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC
| |
Collapse
|
4
|
Dang Y, van Heusden C, Nickerson V, Chung F, Wang Y, Quinney NL, Gentzsch M, Randell SH, Moulton HM, Kole R, Ni A, Juliano RL, Kreda SM. Enhanced delivery of peptide-morpholino oligonucleotides with a small molecule to correct splicing defects in the lung. Nucleic Acids Res 2021; 49:6100-6113. [PMID: 34107015 PMCID: PMC8216463 DOI: 10.1093/nar/gkab488] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Revised: 05/13/2021] [Accepted: 05/21/2021] [Indexed: 02/06/2023] Open
Abstract
Pulmonary diseases offer many targets for oligonucleotide therapeutics. However, effective delivery of oligonucleotides to the lung is challenging. For example, splicing mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) affect a significant cohort of Cystic Fibrosis (CF) patients. These individuals could potentially benefit from treatment with splice switching oligonucleotides (SSOs) that can modulate splicing of CFTR and restore its activity. However, previous studies in cell culture used oligonucleotide transfection methods that cannot be safely translated in vivo. In this report, we demonstrate effective correction of a splicing mutation in the lung of a mouse model using SSOs. Moreover, we also demonstrate effective correction of a CFTR splicing mutation in a pre-clinical CF patient-derived cell model. We utilized a highly effective delivery strategy for oligonucleotides by combining peptide-morpholino (PPMO) SSOs with small molecules termed OECs. PPMOs distribute broadly into the lung and other tissues while OECs potentiate the effects of oligonucleotides by releasing them from endosomal entrapment. The combined PPMO plus OEC approach proved to be effective both in CF patient cells and in vivo in the mouse lung and thus may offer a path to the development of novel therapeutics for splicing mutations in CF and other lung diseases.
Collapse
Affiliation(s)
- Yan Dang
- Marsico Lung Institute/Cystic Fibrosis Center, The University of North Carolina at Chapel Hill, 6009 Thurston Bowles Bldg, Chapel Hill NC 27599-7248, USA
| | - Catharina van Heusden
- Marsico Lung Institute/Cystic Fibrosis Center, The University of North Carolina at Chapel Hill, 6009 Thurston Bowles Bldg, Chapel Hill NC 27599-7248, USA
| | - Veronica Nickerson
- Marsico Lung Institute/Cystic Fibrosis Center, The University of North Carolina at Chapel Hill, 6009 Thurston Bowles Bldg, Chapel Hill NC 27599-7248, USA
| | - Felicity Chung
- Marsico Lung Institute/Cystic Fibrosis Center, The University of North Carolina at Chapel Hill, 6009 Thurston Bowles Bldg, Chapel Hill NC 27599-7248, USA
| | - Yang Wang
- Marsico Lung Institute/Cystic Fibrosis Center, The University of North Carolina at Chapel Hill, 6009 Thurston Bowles Bldg, Chapel Hill NC 27599-7248, USA
| | - Nancy L Quinney
- Marsico Lung Institute/Cystic Fibrosis Center, The University of North Carolina at Chapel Hill, 6009 Thurston Bowles Bldg, Chapel Hill NC 27599-7248, USA
| | - Martina Gentzsch
- Marsico Lung Institute/Cystic Fibrosis Center, The University of North Carolina at Chapel Hill, 6009 Thurston Bowles Bldg, Chapel Hill NC 27599-7248, USA
| | - Scott H Randell
- Marsico Lung Institute/Cystic Fibrosis Center, The University of North Carolina at Chapel Hill, 6009 Thurston Bowles Bldg, Chapel Hill NC 27599-7248, USA
| | - Hong M Moulton
- Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA
| | - Ryszard Kole
- Department of Pharmacology, The University of North Carolina at Chapel Hill, 4010 Genetic Medicine Bldg, Chapel Hill, NC 27599, USA
| | - Aiguo Ni
- Initos Pharmaceuticals, LLC, Chapel Hill, NC 27514, USA
| | | | - Silvia M Kreda
- Marsico Lung Institute/Cystic Fibrosis Center, The University of North Carolina at Chapel Hill, 6009 Thurston Bowles Bldg, Chapel Hill NC 27599-7248, USA
| |
Collapse
|
5
|
Mahato B, Kaya KD, Fan Y, Sumien N, Shetty RA, Zhang W, Davis D, Mock T, Batabyal S, Ni A, Mohanty S, Han Z, Farjo R, Forster MJ, Swaroop A, Chavala SH. Pharmacologic fibroblast reprogramming into photoreceptors restores vision. Nature 2020; 581:83-88. [PMID: 32376950 PMCID: PMC7469946 DOI: 10.1038/s41586-020-2201-4] [Citation(s) in RCA: 54] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Accepted: 02/10/2020] [Indexed: 12/14/2022]
Abstract
Photoreceptor loss is the final common endpoint in most retinopathies that lead to irreversible blindness, and there are no effective treatments to restore vision1,2. Chemical reprogramming of fibroblasts offers an opportunity to reverse vision loss; however, the generation of sensory neuronal subtypes such as photoreceptors remains a challenge. Here we report that the administration of a set of five small molecules can chemically induce the transformation of fibroblasts into rod photoreceptor-like cells. The transplantation of these chemically induced photoreceptor-like cells (CiPCs) into the subretinal space of rod degeneration mice (homozygous for rd1, also known as Pde6b) leads to partial restoration of the pupil reflex and visual function. We show that mitonuclear communication is a key determining factor for the reprogramming of fibroblasts into CiPCs. Specifically, treatment with these five compounds leads to the translocation of AXIN2 to the mitochondria, which results in the production of reactive oxygen species, the activation of NF-κB and the upregulation of Ascl1. We anticipate that CiPCs could have therapeutic potential for restoring vision.
Collapse
Affiliation(s)
- Biraj Mahato
- Department of Pharmacology and Neuroscience, Laboratory for Retinal Rehabilitation, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - Koray Dogan Kaya
- Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, MD, USA
| | - Yan Fan
- Department of Pharmacology and Neuroscience, Laboratory for Retinal Rehabilitation, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - Nathalie Sumien
- Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - Ritu A Shetty
- Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - Wei Zhang
- Department of Pharmacology and Neuroscience, Laboratory for Retinal Rehabilitation, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - Delaney Davis
- Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - Thomas Mock
- Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA
| | | | - Aiguo Ni
- Department of Pharmacology and Neuroscience, Laboratory for Retinal Rehabilitation, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA
| | | | - Zongchao Han
- Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | | | - Michael J Forster
- Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - Anand Swaroop
- Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, MD, USA
| | - Sai H Chavala
- Department of Pharmacology and Neuroscience, Laboratory for Retinal Rehabilitation, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA.
- CIRC Therapeutics, Inc., Dallas, TX, USA.
| |
Collapse
|
6
|
Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol 2019; 29:2085-2091. [PMID: 30165371 DOI: 10.1093/annonc/mdy334] [Citation(s) in RCA: 204] [Impact Index Per Article: 40.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Background MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung cancers in prospective trials. In contrast, the activity of immunotherapy, PD-L1 expression and tumor mutational burden (TMB) of these tumors and are not well characterized. Patients and methods Patients with MET exon 14-altered lung cancers of any stage treated at two academic institutions were identified. A review of clinicopathologic and molecular features, and an analysis of response to single-agent or combination immune checkpoint inhibition were conducted. PD-L1 immunohistochemistry was carried out and TMB was calculated by estimation from targeted next-generation sequencing panels. Results We identified 147 patients with MET exon 14-altered lung cancers. PD-L1 expression of 0%, 1%-49%, and ≥50% were 37%, 22%, and 41%, respectively, in 111 evaluable tumor samples. The median TMB of MET exon 14-altered lung cancers was lower than that of unselected non-small-cell lung cancers (NSCLCs) in both independently evaluated cohorts: 3.8 versus 5.7 mutations/megabase (P < 0.001, n = 78 versus 1769, cohort A), and 7.3 versus 11.8 mutations/megabase (P < 0.001, n = 62 versus 1100, cohort B). There was no association between PD-L1 expression and TMB (Spearman's rho=0.18, P = 0.069). In response-evaluable patients (n = 24), the objective response rate was 17% (95% CI 6% to 36%) and the median progression-free survival was 1.9 months (95% CI 1.7-2.7). Responses were not enriched in tumors with PD-L1 expression ≥50% nor high TMB. Conclusion A substantial proportion of MET exon 14-altered lung cancers express PD-L1, but the median TMB is lower compared with unselected NSCLCs. Occasional responses to PD-1 blockade can be achieved, but overall clinical efficacy is modest.
Collapse
Affiliation(s)
- J K Sabari
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - G C Leonardi
- Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - C A Shu
- Division of Hematology Oncology, Department of Medicine, Columbia University, New York, USA
| | - R Umeton
- Department of Informatics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - J Montecalvo
- Department of Pathology, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA
| | - A Ni
- Department of Epidemiology and Biostatistics, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA
| | - R Chen
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - J Dienstag
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - C Mrad
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - I Bergagnini
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - W V Lai
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - M Offin
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - K C Arbour
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - A J Plodkowski
- Department of Radiology, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA
| | - D F Halpenny
- Department of Radiology, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA
| | - P K Paik
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - B T Li
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA; Department of Early Drug Development Service, Division of Solid Tumor Oncology, Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA
| | - G J Riely
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - M G Kris
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - C M Rudin
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - L M Sholl
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
| | - M Nishino
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA; Department of Radiology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - M D Hellmann
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - N Rekhtman
- Department of Informatics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - M M Awad
- Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - A Drilon
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA; Department of Early Drug Development Service, Division of Solid Tumor Oncology, Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA.
| |
Collapse
|
7
|
Jatana C, Jacobs T, Towning C, Guo X, Ni A, Towning L. The Addition of Platelet-Rich-Fibrin in Socket Preservation for Future Dental Implant Placement: A Randomized Controlled Clinical Trial. J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.joms.2019.06.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Ghione P, Cordeiro P, Ni A, Hu Q, Ganesan N, Galasso N, Dogan A, Horwitz S. RISK OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA-ALCL) IN A COHORT OF 3546 WOMEN PROSPECTIVELY FOLLOWED AFTER RECEIVING TEXTURED BREAST IMPLANTS. Hematol Oncol 2019. [DOI: 10.1002/hon.62_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Ghione
- Lymphoma service; Memorial Sloan Ketterin Cancer Center; New York United States
| | - P.G. Cordeiro
- Department of Surgery; Memorial Sloan Kettering Cancer Center, Plastic and Reconstructive Surgery Service; New York United States
| | - A. Ni
- Biostatistics Department; Memorial Sloan Kettering Cancer Center; New York United States
| | - Q. Hu
- Department of Surgery; Memorial Sloan Kettering Cancer Center, Plastic and Reconstructive Surgery Service; New York United States
| | - N. Ganesan
- Lymphoma service; Memorial Sloan Ketterin Cancer Center; New York United States
| | - N. Galasso
- Lymphoma service; Memorial Sloan Ketterin Cancer Center; New York United States
| | - A. Dogan
- Hematopathology Service; Memorial Sloan Kettering Cancer Center; New York United States
| | - S.M. Horwitz
- Lymphoma service; Memorial Sloan Ketterin Cancer Center; New York United States
| |
Collapse
|
9
|
Matasar M, Qiu A, Shapouri S, Drill E, Schade J, Ravelo A, Ni A, To T, Dawson K. REAL-WORLD ASSESSMENT OF PRACTICE EFFICIENCY WITH THE INTRODUCTION OF SUBCUTANEOUS RITUXIMAB. Hematol Oncol 2019. [DOI: 10.1002/hon.226_2631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M.J. Matasar
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - A. Qiu
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - S. Shapouri
- US Medical Affairs; Genentech, Inc.; South San Francisco CA United States
| | - E.N. Drill
- Department of Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - J. Schade
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - A. Ravelo
- US Medical Affairs; Genentech, Inc.; South San Francisco CA United States
| | - A. Ni
- Department of Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - T.M. To
- US Medical Affairs; Genentech, Inc.; South San Francisco CA United States
| | - K.L. Dawson
- US Medical Affairs; Genentech, Inc.; South San Francisco CA United States
| |
Collapse
|
10
|
Batlevi C, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Hamlin P, Horwitz S, Kumar A, Matasar M, Moskowitz A, Moskowitz C, Noy A, Palomba M, Portlock C, Straus D, Boccomini C, Tucci A, Zelenetz A, Seshan V, Luminari S, Marcheselli L, Federico M, Younes A. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.109_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- C.L. Batlevi
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - F. Sha
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Alperovich
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Ni
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - K. Smith
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - Z. Ying
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - P. Hamlin
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - S.M. Horwitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Kumar
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - M. Matasar
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A.J. Moskowitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C.H. Moskowitz
- Department of Medicine; University of Miami, Sylvester Cancer Center; Miami United States
| | - A. Noy
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - M.L. Palomba
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C. Portlock
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - D. Straus
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C. Boccomini
- ASO Città della Salute e della Scienza di Torino; Ematologia; Turin Italy
| | - A. Tucci
- Department of Hematology; Spedali Civili di Brescia; Brescia Italy
| | - A.D. Zelenetz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - V.E. Seshan
- Department of Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center; New York United States
| | - S. Luminari
- Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine, Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine; University of Modena and Reggio Emilia; Modena Italy
| | - L. Marcheselli
- Department of Medical and Surgical Sciences, and FIL Trial Office; University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine, Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine; University of Modena and Reggio Emilia; Modena Italy
| | - A. Younes
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| |
Collapse
|
11
|
Sun Y, Liu Y, Li Y, Bai H, Ni A, Chen J. 307 Identification and differential expression of microRNAs in the testis of chicken with high and low sperm motility. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Y Sun
- Institute of Animal Science, Chinese Academy of Agricultural Sciences,Beijing, China
| | - Y Liu
- Institute of Animal Science, Chinese Academy of Agricultural Sciences,Beijing, China
| | - Y Li
- Institute of Animal Science, Chinese Academy of Agricultural Sciences,Beijing, China
| | - H Bai
- Institute of Animal Science, Chinese Academy of Agricultural Sciences,Beijing, China
| | - A Ni
- Institute of Animal Science, Chinese Academy of Agricultural Sciences,Beijing, China
| | - J Chen
- Institute of Animal Science, Chinese Academy of Agricultural Sciences,Beijing, China
| |
Collapse
|
12
|
Zauderer M, Muller S, Lai W, Ni A, Jungbluth A, Ginsberg M, Daly R, Hellmann M, Ladanyi M, Sauter J. P2.06-40 VISTA is Highly Expressed in Malignant Pleural Mesothelioma (MPM) and Independent of PD-L1 Expression. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Arbour K, Shen R, Plodkowski A, Rizvi H, Ni A, Long N, Halpenny D, Sanchez-Vega F, Rudin C, Riely G, Hellmann M. MA19.09 Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L)1 Blockade in Patients with NSCLC Despite High TMB. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.480] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Ponce S, Allison MA, Swett K, Cai J, Desai AA, Hurwitz BE, Ni A, Schneiderman N, Shah SJ, Spevack DM, Talavera GA, Rodriguez CJ. The associations between anthropometric measurements and left ventricular structure and function: the Echo-SOL Study. Obes Sci Pract 2018; 4:387-395. [PMID: 30151233 PMCID: PMC6105700 DOI: 10.1002/osp4.279] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 04/13/2018] [Accepted: 04/26/2018] [Indexed: 12/30/2022] Open
Abstract
OBJECTIVE The objective of this study is to determine associations between anthropometry and echocardiographic measures of cardiac structure and function in Hispanic/Latinos. METHODS A total of 1,824 participants from ECHO-SOL were included. We evaluated associations between echocardiographic measures of left ventricular structure and function and anthropometric measures using multivariable-adjusted linear and logistic regression models adjusting for traditional cardiovascular risk factors. RESULTS The mean age was 56 ± 0.17 years, 57% were women. The mean body mass index (BMI) was 30 ± 9.4 kg m-2, waist circumference (WC) was 100 ± 18 cm, and waist-to-hip ratio (WHR) was 0.93 ± 0.15. Adjusted analysis showed that 5-unit increment in BMI and 5-cm increase in WC was associated with 3.4 ± 0.6 and 1.05 ± 0.05 g m-2.7 (p < 0.05 for both) higher left ventricular (LV) mass index, respectively. Similarly, 0.1-unit increment in WHR was associated with 2.0 ± 0.16 g m-2.7 higher LV mass index (p < 0.01). WHR was associated with 0.22 ± 0.08% decrease in ejection fraction (p < 0.05). Concomitantly, 5-unit increment in BMI and WC was associated with increased odds of abnormal LV geometry (odds ratio 1.40 and 1.16, p = 0.03 and <0.01, respectively); 0.1-unit increment in WHR was associated with increased odds of abnormal LV geometry (odds ratio 1.51, p < 0.01). CONCLUSIONS Among Hispanic/Latinos, higher anthropometric measures were associated with adverse cardiac structure and function.
Collapse
Affiliation(s)
- S. Ponce
- Family Medicine and Public Health DepartmentUniversity of California San DiegoLa JollaCAUSA
| | - M. A. Allison
- Family Medicine and Public Health DepartmentUniversity of California San DiegoLa JollaCAUSA
| | - K. Swett
- Biostatistics DepartmentUniversity of North CarolinaChapel HillNCUSA
| | - J. Cai
- Biostatistics DepartmentUniversity of North CarolinaChapel HillNCUSA
| | - A. A. Desai
- Department of MedicineUniversity of ArizonaTucsonAZUSA
| | - B. E. Hurwitz
- Department of PsychologyUniversity of MiamiCoral GablesFLUSA
| | - A. Ni
- Biostatistics DepartmentUniversity of North CarolinaChapel HillNCUSA
| | - N. Schneiderman
- Department of PsychologyUniversity of MiamiCoral GablesFLUSA
| | - S. J. Shah
- Department of MedicineNorthwestern UniversityEvanstonILUSA
| | - D. M. Spevack
- Department of MedicineAlbert Einstein College of MedicineBronxNYUSA
| | - G. A. Talavera
- Graduate School of Public HealthSan Diego State UniversitySan DiegoCAUSA
| | - C. J. Rodriguez
- Epidemiology and PreventionWake Forest UniversityWinston‐SalemNCUSA
| |
Collapse
|
15
|
Bai H, Sun Y, Liu N, Liu Y, Xue F, Li Y, Xu S, Ni A, Ye J, Chen Y, Chen J. Genome-wide detection of CNVs associated with beak deformity in chickens using high-density 600K SNP arrays. Anim Genet 2018; 49:226-236. [PMID: 29642269 DOI: 10.1111/age.12652] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/07/2018] [Indexed: 11/30/2022]
Abstract
Beak deformity (crossed beaks) is found in several indigenous chicken breeds including Beijing-You studied here. Birds with deformed beaks have reduced feed intake and poor production performance. Recently, copy number variation (CNV) has been examined in many species and is recognized as a source of genetic variation, especially for disease phenotypes. In this study, to unravel the genetic mechanisms underlying beak deformity, we performed genome-wide CNV detection using Affymetrix chicken high-density 600K data on 48 deformed-beak and 48 normal birds using penncnv. As a result, two and eight CNV regions (CNVRs) covering 0.32 and 2.45 Mb respectively on autosomes were identified in deformed-beak and normal birds respectively. Further RT-qPCR studies validated nine of the 10 CNVRs. The ratios of six CNVRs were significantly different between deformed-beak and normal birds (P < 0.01). Within these six regions, three and 21 known genes were identified in deformed-beak and normal birds respectively. Bioinformatics analysis showed that these genes were enriched in six GO terms and one KEGG pathway. Five candidate genes in the CNVRs were further validated using RT-qPCR. The expression of LRIG2 (leucine rich repeats and immunoglobulin like domains 2) was lower in birds with deformed beaks (P < 0.01). Therefore, the LRIG2 gene could be considered a key factor in view of its known functions and its potential roles in beak deformity. Overall, our results will be helpful for future investigations of the genomic structural variations underlying beak deformity in chickens.
Collapse
Affiliation(s)
- H Bai
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - Y Sun
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - N Liu
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - Y Liu
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - F Xue
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - Y Li
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - S Xu
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - A Ni
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - J Ye
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - Y Chen
- Beijing General Station of Animal Husbandry Service, Beijing, 102200, China
| | - J Chen
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| |
Collapse
|
16
|
Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 2017; 28:583-589. [PMID: 27998967 DOI: 10.1093/annonc/mdw640] [Citation(s) in RCA: 441] [Impact Index Per Article: 63.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Background Programmed cell death protein-1 (PD-1) blockade therapies have demonstrated durable responses and prolonged survival in a variety of malignancies. Treatment is generally well tolerated although immune-related adverse events (irAEs) can occur. Autoimmune thyroid dysfunction is among the most common irAE, but an assessment of the clinical, mechanistic, and immunologic features has not been previously described. Patient and methods Patients with advanced non-small-cell lung cancer (NSCLC) treated with pembrolizumab at Memorial Sloan Kettering Cancer Center (n = 51) as part of KEYNOTE-001 (NCT01295827) were included. Thyroid function test and anti-thyroid antibodies were assessed prospectively at each study visit, beginning before the first treatment. Frequency of development of thyroid dysfunction, association with anti-thyroid antibodies, clinical course, and relationship with progression-free survival and overall survival to treatment with pembrolizumab was evaluated. Results Of 51 patients treated, 3 were hypothyroid and 48 were not at baseline. Ten of 48 [21%, 95% confidence interval (CI) 10% to 35%] patients developed thyroid dysfunction requiring thyroid replacement. Anti-thyroid antibodies were present in 8 of 10 patients who developed thyroid dysfunction, compared with 3 of 38 who did not (80% versus 8%, P < 0.0001). Thyroid dysfunction occurred early (median, 42 days) in the pembrolizumab course, and a majority (6 of 10 patients) experienced brief, transient hyperthyroidism preceding the onset of hypothyroidism; no persistent hyperthyroidism occurred. Both hyperthyroidism and hypothyroidism were largely asymptomatic. Overall survival with pembrolizumab was significantly longer in subjects who developed thyroid dysfunction (hazard ratio, 0.29; 95% CI 0.09-0.94; P = 0.04). Conclusions Thyroid dysfunction during pembrolizumab treatment of NSCLC is common and is characterized by early-onset, frequently preceded by transient hyperthyroidism, closely associated with anti-thyroid antibodies, and may be associated with improved outcomes. The presence of antibody-mediated toxicity in T-cell-directed therapy suggests an under-recognized impact of PD-1 biology in modulating humoral immunity.
Collapse
Affiliation(s)
- J C Osorio
- Department of Medicine, Weill Cornell Medical College, New York, USA
| | - A Ni
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
| | - J E Chaft
- Department of Medicine, Weill Cornell Medical College, New York, USA,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - R Pollina
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - M K Kasler
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - D Stephens
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - C Rodriguez
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - L Cambridge
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - H Rizvi
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - J D Wolchok
- Department of Medicine, Weill Cornell Medical College, New York, USA,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA,Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering, New York, , USA,Ludwig Institute for Cancer Research, New York, USA
| | - T Merghoub
- Department of Medicine, Weill Cornell Medical College, New York, USA,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA,Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering, New York, , USA,Ludwig Institute for Cancer Research, New York, USA
| | - C M Rudin
- Department of Medicine, Weill Cornell Medical College, New York, USA,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - S Fish
- Department of Medicine, Weill Cornell Medical College, New York, USA,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - M D Hellmann
- Department of Medicine, Weill Cornell Medical College, New York, USA,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA,Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering, New York, , USA
| |
Collapse
|
17
|
Li B, Shen R, Buonocore D, Olah Z, Ni A, Ginsberg M, Ulaner G, Weber W, Tsui D, Offin M, Won H, Ladanyi M, Riely G, Solit D, Hyman D, Rudin C, Berger M, Baselga J, Scaltriti M, Arcila M, Kris M. OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.410] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Sauter C, Riviere I, Senechal B, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Moskowitz C, Giralt S, Matasar M, Curran K, Park J, Sadelain M, Brentjens R. A PHASE I TRIAL OF 19-28Z CAR-T CELLS POST-HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT-ASCT) FOR RELAPSED AND REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_128] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Sauter
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - I. Riviere
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - B. Senechal
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Ni
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - Y. Bernal
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - X. Wang
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - T. Purdon
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Hall
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Moskowitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Giralt
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Matasar
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - K. Curran
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Park
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Sadelain
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - R. Brentjens
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
19
|
Batlevi C, Alperovich A, Ni A, Soumerai J, Smith K, Ying Z, Caron P, Drullinsky P, Gerecitano J, Hamilton A, Hamlin P, Horwitz S, Kumar A, Matasar M, Moskowitz A, Moskowitz C, Noy A, Palomba M, Portlock C, Sauter C, Straus D, Zelenetz A, Seshan V, Younes A. DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_92] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | | | - A. Ni
- Biostatistics, MKSCC; New York USA
| | | | | | - Z. Ying
- Hematology; Peking University Cancer Hospital; Beijing China
| | | | | | | | | | | | | | | | | | | | | | - A. Noy
- Lymphoma, MSKCC; New York USA
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Batlevi C, Hamlin P, Matasar M, Gerecitano J, Drullinsky P, Hamilton A, Straus D, Horwitz S, Kumar A, Moskowitz C, Moskowitz A, Zelenetz A, Ahsanuddin S, Callan D, Freidin B, Porzio R, Soiffer J, Copeland A, Dang T, Rademaker J, Schoder H, Ni A, Younes A. PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_38] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Batlevi
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Hamlin
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Matasar
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Gerecitano
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Drullinsky
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Hamilton
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - D. Straus
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Horwitz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Kumar
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Moskowitz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Moskowitz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Zelenetz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Ahsanuddin
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - D. Callan
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - B. Freidin
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - R. Porzio
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Soiffer
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Copeland
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - T. Dang
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Rademaker
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - H. Schoder
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Ni
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Younes
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
21
|
Moskowitz A, Schöder H, Gavane S, Thoren K, Fleisher M, Yahalom J, McCall S, Fox S, Gerecitano J, Grewal R, Hamlin P, Horwitz S, Kumar A, Matasar M, Ni A, Noy A, Palomba M, Perales M, Portlock C, Sauter C, Straus D, Younes A, Zelenetz A, Moskowitz C. BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET-ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_17] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A.J. Moskowitz
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - H. Schöder
- Nuclear Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Gavane
- Nuclear Medicine; Mt. Sinai Hospital; New York USA
| | - K.L. Thoren
- Clinical Chemistry Service; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Fleisher
- Clinical Chemistry Service; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Yahalom
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - S.J. McCall
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - S.Y. Fox
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Gerecitano
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - R. Grewal
- Nuclear Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P.A. Hamlin
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Horwitz
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Kumar
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Matasar
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Ni
- Biostatistics; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Noy
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - M.L. Palomba
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Perales
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - C.S. Portlock
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Sauter
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - D. Straus
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Younes
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - A.D. Zelenetz
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - C.H. Moskowitz
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
22
|
Soumerai J, Ni A, Batlevi C, Alperovich A, Bantilan K, Palomba M, Gerecitano J, Noy A, Hamlin P, Moskowitz C, Copeland A, Matasar M, Drullinsky P, Hamilton A, Horwitz S, Intlekofer A, Kumar A, Moskowitz A, Portlock C, Sauter C, Straus D, Caron P, Ying Z, Smith K, Younes A, Zelenetz A. TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_93] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J.D. Soumerai
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Ni
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Batlevi
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Alperovich
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - K.S. Bantilan
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Palomba
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - J.F. Gerecitano
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Noy
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Hamlin
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - C.H. Moskowitz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A.R. Copeland
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - M.J. Matasar
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - P.R. Drullinsky
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Hamilton
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - S.M. Horwitz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A.M. Intlekofer
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Kumar
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Moskowitz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Portlock
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Sauter
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - D.J. Straus
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Caron
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - Z. Ying
- Medicine, Royal Marsden Hospital; Beigene China
| | - K. Smith
- Medicine, Royal Marsden Hospital; London UK
| | - A. Younes
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A.D. Zelenetz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
23
|
Ho AL, Dunn L, Sherman EJ, Fury MG, Baxi SS, Chandramohan R, Dogan S, Morris LGT, Cullen GD, Haque S, Sima CS, Ni A, Antonescu CR, Katabi N, Pfister DG. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol 2016; 27:1902-8. [PMID: 27566443 DOI: 10.1093/annonc/mdw287] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Accepted: 07/19/2016] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Recurrent/metastatic adenoid cystic carcinoma (ACC) is an incurable disease with no standard treatments. The majority of ACCs express the oncogenic transcription factor MYB (also c-myb), often in the context of a MYB gene rearrangement. This phase II trial of the tyrosine kinase inhibitor (TKI) axitinib (Pfizer) tested the hypothesis that targeting pathways activated by MYB can be therapeutically effective for ACC. PATIENTS AND METHODS This is a minimax two-stage, phase II trial that enrolled patients with incurable ACC of any primary site. Progressive or symptomatic disease was required. Patients were treated with axitinib 5 mg oral twice daily; dose escalation was allowed. The primary end point was best overall response (BOR). An exploratory analysis correlating biomarkers to drug benefit was conducted, including next-generation sequencing (NGS) in 11 patients. RESULTS Thirty-three patients were registered and evaluable for response. Fifteen patients had the axitinib dose increased. Tumor shrinkage was achieved in 22 (66.7%); 3 (9.1%) had confirmed partial responses. Twenty-five (75.8%) patients had stable disease, 10 of whom had disease stability for >6 months. The median progression-free survival (PFS) was 5.7 months (range 0.92-21.8 months). Grade 3 axitinib-related toxicities included hypertension, oral pain and fatigue. A trend toward superior PFS was noted with the MYB/NFIB rearrangement, although this was not statistically significant. NGS revealed three tumors with 4q12 amplification, producing increased copies of axitinib-targeted genes PDGFR/KDR/KIT. Two 4q12 amplified patients achieved stable disease for >6 months, including one with significant tumor reduction and the longest PFS on study (21.8 months). CONCLUSIONS Although the primary end point was not met, axitinib exhibited clinical activity with tumor shrinkage achieved in the majority of patients with progressive disease before trial enrollment. Analysis of MYB biomarkers and genomic profiling suggests the hypothesis that 4q12 amplified ACCs are a disease subset that benefit from TKI therapy.
Collapse
Affiliation(s)
- A L Ho
- Department of Medicine Department of Medicine
| | | | - E J Sherman
- Department of Medicine Department of Medicine
| | - M G Fury
- Department of Medicine Department of Medicine
| | - S S Baxi
- Department of Medicine Department of Medicine
| | | | | | - L G T Morris
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, USA
| | | | - S Haque
- Department of Radiology Department of Radiology, Weill Cornell Medical College, New York City
| | - C S Sima
- Department of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, USA
| | - A Ni
- Department of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, USA
| | | | | | - D G Pfister
- Department of Medicine Department of Medicine
| |
Collapse
|
24
|
Ni A, Wu MJ, Chavala SH. Sphere formation permits Oct4 reprogramming of ciliary body epithelial cells into induced pluripotent stem cells. Stem Cells Dev 2015; 23:3065-71. [PMID: 25027059 DOI: 10.1089/scd.2014.0064] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Somatic cells can be reprogrammed to induced pluripotent stem (iPS) cells by defined sets of transcription factors. We previously described reprogramming of monolayer-cultured adult mouse ciliary body epithelial (CE) cells by Oct4 and Klf4, but not with Oct4 alone. In this study, we report that Oct4 alone is sufficient to reprogram CE cells to iPS cells through sphere formation. Furthermore, we demonstrate that sphere formation induces a partial reprogramming state characterized by expression of retinal progenitor markers, upregulation of reprogramming transcription factors, such as Sall4 and Nanog, demethylation in the promoter regions of pluripotency associated genes, and mesenchymal to epithelial transition. The Oct4-iPS cells maintained normal karyotypes, expressed markers for pluripotent stem cells, and were capable of differentiating into derivatives of all three embryonic germ layers in vivo and in vitro. These findings suggest that sphere formation may render somatic cells more susceptible to reprogramming.
Collapse
Affiliation(s)
- Aiguo Ni
- Department of Ophthalmology, University of North Carolina , Chapel Hill, North Carolina
| | | | | |
Collapse
|
25
|
Aziz MK, Ni A, Esserman DA, Chavala SH. Evidence of early ultrastructural photoreceptor abnormalities in light-induced retinal degeneration using spectral domain optical coherence tomography. Br J Ophthalmol 2014; 98:984-9. [PMID: 24671925 DOI: 10.1136/bjophthalmol-2013-304515] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND To study spatiotemporal in vivo changes in retinal morphology and quantify thickness of retinal layers in a mouse model of light-induced retinal degeneration using spectral domain optical coherence tomography (SD-OCT). METHODS BALB/c mice were exposed to 5000 lux of constant light for 3 h. SD-OCT images were taken 3 h, 24 h, 3 days, 1 week and 1 month after light exposure and were compared with histology at the same time points. SD-OCT images were also taken at 0, 1 and 2 h after light exposure in order to analyse retinal changes at the earliest time points. The thickness of retinal layers was measured using the Bioptigen software InVivoVue Diver. RESULTS SD-OCT demonstrated progressive outer retinal thinning. 3 h after light exposure, the outer nuclear layer converted from hyporeflective to hyper-reflective. At 24 h, outer retinal bands and nuclear layer demonstrated similar levels of hyper-reflectivity. Significant variations in outer retinal thickness, vitreous opacities and retinal detachments occurred within days of injury. Thinning of the retina was observed at 1 month after injury. It was also determined that outer nuclear layer changes precede photoreceptor segment structure disintegration and the greatest change in segment structure occurs between 1 and 2 h after light exposure. CONCLUSIONS Longitudinal SD-OCT reveals intraretinal changes that cannot be observed by histopathology at early time points in the light injury model.
Collapse
Affiliation(s)
- Mehak K Aziz
- Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina, USA
| | - Aiguo Ni
- Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina, USA
| | - Denise A Esserman
- Departments of Medicine, Division of General Medicine and Clinical Epidemiology and Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA
| | - Sai H Chavala
- Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina, USA
| |
Collapse
|
26
|
Sako H, Ahn JK, Baek KY, Bassalleck B, Fujioka H, Guo L, Hasegawa S, Hicks K, Honda R, Hwang SH, Ichikawa Y, Ieiri M, Imai K, Kim SH, Kiuchi R, Lee HS, Nakazawa K, Naruki M, Ni A, Niiyama M, Ozawa K, Park JY, Park SH, Ryu SY, Sato S, Shirotori K, Sugimura H, Sumihara M, Tanida K, Takahashi H, Takahashi T. Search for H-dibaryon at J-PARC with a Large Acceptance TPC. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20146609015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Ni A, Wu MJ, Nakanishi Y, Chavala SH. Facile and efficient reprogramming of ciliary body epithelial cells into induced pluripotent stem cells. Stem Cells Dev 2013; 22:2543-50. [PMID: 23635313 DOI: 10.1089/scd.2012.0600] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Induced pluripotent stem (iPS) cells are attractive for cell replacement therapy, because they overcome ethical and immune rejection issues that are associated with embryonic stem cells. iPS cells have been derived from autonomous fibroblasts at low efficiency using multiple ectopic transcription factors. Recent evidence suggests that the epigenome of donor cell sources plays an important role in the reprogramming and differentiation characteristics of iPS cells. Thus, identification of somatic cell types that are easily accessible and are more amenable for cellular reprogramming is critical for regenerative medicine applications. Here, we identify ciliary body epithelial cells (CECs) as a new cell type for iPS cell generation that has higher reprogramming efficiency compared with fibroblasts. The ciliary body is composed of epithelial cells that are located in the anterior portion of the eye at the level of the lens and is readily surgically accessible. CECs also have a reduced reprogramming requirement, as we demonstrate that ectopic Sox2 and c-Myc are dispensable. Enhanced reprogramming efficiency may be due to increased basal levels of Sox2 in CECs. In addition, we are the first to report a cellular reprogramming haploinsufficiency observed when reprogramming with fewer factors (Oct4 and Klf4) in Sox2 hemizygous cells. Taken together, endogenous Sox2 levels are critical for the enhanced efficiency and reduced exogenous requirement that permit facile cellular reprogramming of CECs.
Collapse
Affiliation(s)
- Aiguo Ni
- Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina 27599-7040, USA
| | | | | | | |
Collapse
|
28
|
Baillie N, Tkachenko S, Zhang J, Bosted P, Bültmann S, Christy ME, Fenker H, Griffioen KA, Keppel CE, Kuhn SE, Melnitchouk W, Tvaskis V, Adhikari KP, Adikaram D, Aghasyan M, Amaryan MJ, Anghinolfi M, Arrington J, Avakian H, Baghdasaryan H, Battaglieri M, Biselli AS, Branford D, Briscoe WJ, Brooks WK, Burkert VD, Carman DS, Celentano A, Chandavar S, Charles G, Cole PL, Contalbrigo M, Crede V, D'Angelo A, Daniel A, Dashyan N, De Vita R, De Sanctis E, Deur A, Dey B, Djalali C, Dodge G, Domingo J, Doughty D, Dupre R, Dutta D, Ent R, Egiyan H, El Alaoui A, El Fassi L, Elouadrhiri L, Eugenio P, Fedotov G, Fegan S, Fradi A, Gabrielyan MY, Gevorgyan N, Gilfoyle GP, Giovanetti KL, Girod FX, Gohn W, Golovatch E, Gothe RW, Graham L, Guegan B, Guidal M, Guler N, Guo L, Hafidi K, Heddle D, Hicks K, Holtrop M, Hungerford E, Hyde CE, Ilieva Y, Ireland DG, Ispiryan M, Isupov EL, Jawalkar SS, Jo HS, Kalantarians N, Khandaker M, Khetarpal P, Kim A, Kim W, King PM, Klein A, Klein FJ, Klimenko A, Kubarovsky V, Kuleshov SV, Kvaltine ND, Livingston K, Lu HY, MacGregor IJD, Mao Y, Markov N, McKinnon B, Mineeva T, Morrison B, Moutarde H, Munevar E, Nadel-Turonski P, Ni A, Niccolai S, Niculescu I, Niculescu G, Osipenko M, Ostrovidov AI, Pappalardo L, Park K, Park S, Pasyuk E, Anefalos Pereira S, Pisano S, Pozdniakov S, Price JW, Procureur S, Prok Y, Protopopescu D, Raue BA, Ricco G, Rimal D, Ripani M, Rosner G, Rossi P, Sabatié F, Saini MS, Salgado C, Schott D, Schumacher RA, Seder E, Sharabian YG, Sober DI, Sokhan D, Stepanyan S, Stepanyan SS, Stoler P, Strauch S, Taiuti M, Tang W, Ungaro M, Vineyard MF, Voutier E, Watts DP, Weinstein LB, Weygand DP, Wood MH, Zana L, Zhao B. Measurement of the neutron F2 structure function via spectator tagging with CLAS. Phys Rev Lett 2012; 108:142001. [PMID: 22540786 DOI: 10.1103/physrevlett.108.142001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/12/2011] [Indexed: 05/31/2023]
Abstract
We report on the first measurement of the F(2) structure function of the neutron from the semi-inclusive scattering of electrons from deuterium, with low-momentum protons detected in the backward hemisphere. Restricting the momentum of the spectator protons to ≲100 MeV/c and their angles to ≳100° relative to the momentum transfer allows an interpretation of the process in terms of scattering from nearly on-shell neutrons. The F(2)(n) data collected cover the nucleon-resonance and deep-inelastic regions over a wide range of Bjorken x for 0.65<Q(2)<4.52 GeV(2), with uncertainties from nuclear corrections estimated to be less than a few percent. These measurements provide the first determination of the neutron to proton structure function ratio F(2)(n)/F(2)(p) at 0.2≲x≲0.8 with little uncertainty due to nuclear effects.
Collapse
Affiliation(s)
- N Baillie
- College of William and Mary, Williamsburg, Virginia 23187, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Feber J, Gaboury I, Ni A, Alos N, Arora S, Bell L, Blydt-Hansen T, Clarson C, Filler G, Hay J, Hebert D, Lentle B, Matzinger M, Midgley J, Moher D, Pinsk M, Rauch F, Rodd C, Shenouda N, Siminoski K, Ward LM. Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome. Osteoporos Int 2012; 23:751-60. [PMID: 21494860 PMCID: PMC4000256 DOI: 10.1007/s00198-011-1621-2] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2010] [Accepted: 03/02/2011] [Indexed: 01/27/2023]
Abstract
SUMMARY Eighty children with nephrotic syndrome underwent lumbar spine densitometry and vertebral morphometry soon after glucocorticoid initiation. We found an inverse relationship between glucocorticoid exposure and spine areal bone mineral density (BMD) Z-score and a low rate of vertebral deformities (8%). INTRODUCTION Vertebral fractures are an under-recognized complication of childhood glucocorticoid-treated illnesses. Our goal was to study the relationships among glucocorticoid exposure, lumbar spine areal BMD (LS BMD), and vertebral shape in glucocorticoid-treated children with new-onset nephrotic syndrome. METHODS Lateral thoracolumbar spine radiography and LS BMD were performed in 80 children with nephrotic syndrome (median age 4.4 years; 46 boys) within the first 37 days of glucocorticoid therapy. Genant semiquantitative grading was used as the primary method for vertebral morphometry; the algorithm-based qualitative (ABQ) method was used for secondary vertebral deformity analysis. RESULTS Six of the 78 children with usable radiographs (8%; 95% confidence interval 4 to 16%) manifested a single Genant grade 1 deformity each. All deformities were mild anterior wedging (two at each of T6, T7, and T8). Four of the 78 children (5%; 95% confidence interval 2 to 13%) showed one ABQ sign of fracture each (loss of endplate parallelism; two children at T6 and two at T8). Two of the children with ABQ signs also had a Genant grade 1 deformity in the same vertebral body. None of the children with a Genant or ABQ deformity reported back pain. An inverse relationship was identified between LS BMD Z-score and glucocorticoid exposure. CONCLUSIONS Although we identified an inverse relationship between steroid exposure and LS BMD soon after glucocorticoid initiation for childhood nephrotic syndrome, there was only a low rate of vertebral deformities. The clinical significance of these findings requires further study.
Collapse
Affiliation(s)
- J Feber
- University of Ottawa, Ottawa, ON, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Wood MH, Nasseripour R, Paolone M, Djalali C, Weygand DP, Adhikari KP, Anghinolfi M, Ball J, Battaglieri M, Batourine V, Bedlinskiy I, Bellis M, Berman BL, Biselli AS, Branford D, Briscoe WJ, Brooks WK, Burkert VD, Careccia SL, Carman DS, Cole PL, Collins P, Crede V, D'Angelo A, Daniel A, De Vita R, De Sanctis E, Deur A, Dey B, Dhamija S, Dickson R, Doughty D, Dupre R, Egiyan H, El Alaoui A, El Fassi L, Eugenio P, Fegan S, Gabrielyan MY, Garçon M, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Gohn W, Gothe RW, Graham L, Guidal M, Guo L, Hafidi K, Hakobyan H, Hanretty C, Hassall N, Hicks K, Holtrop M, Ilieva Y, Ireland DG, Ishkhanov BS, Jawalkar SS, Jo HS, Joo K, Keller D, Khandaker M, Khetarpal P, Kim A, Kim W, Klein A, Klein FJ, Konczykowski P, Kubarovsky V, Kuleshov SV, Kuznetsov V, Livingston K, Martinez D, Mayer M, McAndrew J, McCracken ME, McKinnon B, Meyer CA, Mineeva T, Mirazita M, Mokeev V, Moreno B, Moriya K, Morrison B, Munevar E, Nadel-Turonski P, Ni A, Niccolai S, Niculescu G, Niculescu I, Niroula MR, Osipenko M, Ostrovidov AI, Paremuzyan R, Park K, Park S, Pasyuk E, Anefalos Pereira S, Pisano S, Pogorelko O, Pozdniakov S, Price JW, Procureur S, Prok Y, Protopopescu D, Raue BA, Ricco G, Ripani M, Rosner G, Rossi P, Sabatié F, Saini MS, Salamanca J, Salgado C, Schott D, Schumacher RA, Seder E, Seraydaryan H, Sharabian YG, Smith GD, Sober DI, Sokhan D, Stepanyan S, Stepanyan SS, Stoler P, Strakovsky II, Strauch S, Taiuti M, Tang W, Taylor CE, Tedeschi DJ, Tkachenko S, Ungaro M, Vernarsky B, Vineyard MF, Voutier E, Watts DP, Weinstein LB, Zhang J, Zhao B, Zhao ZW. Absorption of the ω and ϕ mesons in nuclei. Phys Rev Lett 2010; 105:112301. [PMID: 20867566 DOI: 10.1103/physrevlett.105.112301] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2010] [Indexed: 05/29/2023]
Abstract
Because of their long lifetimes, the ω and ϕ mesons are the ideal candidates for the study of possible modifications of the in-medium meson-nucleon interaction through their absorption inside the nucleus. During the E01-112 experiment at the Thomas Jefferson National Accelerator Facility, the mesons were photoproduced from 2H, C, Ti, Fe, and Pb targets. This Letter reports the first measurement of the ratio of nuclear transparencies for the e+e- channel. The ratios indicate larger in-medium widths compared with what have been reported in other reaction channels. The absorption of the ω meson is stronger than that reported by the CBELSA-TAPS experiment and cannot be explained by recent theoretical models.
Collapse
Affiliation(s)
- M H Wood
- Canisius College, Buffalo, New York 14208, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Huber AM, Gaboury I, Cabral DA, Lang B, Ni A, Stephure D, Taback S, Dent P, Ellsworth J, LeBlanc C, Saint-Cyr C, Scuccimarri R, Hay J, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care Res (Hoboken) 2010; 62:516-26. [PMID: 20391507 DOI: 10.1002/acr.20171] [Citation(s) in RCA: 106] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVE Vertebral fractures are an under-recognized problem in children with inflammatory disorders. We studied spine health among 134 children (87 girls) with rheumatic conditions (median age 10 years) within 30 days of initiating glucocorticoid therapy. METHODS Children were categorized as follows: juvenile dermatomyositis (n = 30), juvenile idiopathic arthritis (n = 28), systemic lupus erythematosus and related conditions (n = 26), systemic arthritis (n = 22), systemic vasculitis (n = 16), and other conditions (n = 12). Thoracolumbar spine radiograph and dual x-ray absorptiometry for lumbar spine (L-spine) areal bone mineral density (BMD) were performed within 30 days of glucocorticoid initiation. Genant semiquantitative grading was used for vertebral morphometry. Second metacarpal morphometry was carried out on a hand radiograph. Clinical factors including disease and physical activity, calcium and vitamin D intake, cumulative glucocorticoid dose, underlying diagnosis, L-spine BMD Z score, and back pain were analyzed for association with vertebral fracture. RESULTS Thirteen vertebral fractures were noted in 9 children (7%). Of these, 6 patients had a single vertebral fracture and 3 had 2-3 fractures. Fractures were clustered in the mid-thoracic region (69%). Three vertebral fractures (23%) were moderate (grade 2); the others were mild (grade 1). For the entire cohort, mean +/- SD L-spine BMD Z score was significantly different from zero (-0.55 +/- 1.2, P < 0.001) despite a mean height Z score that was similar to the healthy average (0.02 +/- 1.0, P = 0.825). Back pain was highly associated with increased odds for fracture (odds ratio 10.6 [95% confidence interval 2.1-53.8], P = 0.004). CONCLUSION In pediatric rheumatic conditions, vertebral fractures can be present prior to prolonged glucocorticoid exposure.
Collapse
Affiliation(s)
- A M Huber
- Dalhousie University, Halifax, Nova Scotia, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Huang J, Zhang Z, Guo J, Ni A, Deb A, Zhang L, Mirotsou M, Pratt RE, Dzau VJ. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 2010; 106:1753-62. [PMID: 20378860 DOI: 10.1161/circresaha.109.196030] [Citation(s) in RCA: 178] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
RATIONALE Although mesenchymal stem cell (MSC) transplantation has been shown to promote cardiac repair in acute myocardial injury in vivo, its overall restorative capacity appears to be restricted mainly because of poor cell viability and low engraftment in the ischemic myocardium. Specific chemokines are upregulated in the infarcted myocardium. However the expression levels of the corresponding chemokine receptors (eg, CCR1, CXCR2) in MSCs are very low. We hypothesized that this discordance may account for the poor MSC engraftment and survival. OBJECTIVE To determine whether overexpression of CCR1 or CXCR2 chemokine receptors in MSCs augments their cell survival, migration and engraftment after injection in the infarcted myocardium. METHODS AND RESULTS Overexpression of CCR1, but not CXCR2, dramatically increased chemokine-induced murine MSC migration and protected MSC from apoptosis in vitro. Moreover, when MSCs were injected intramyocardially one hour after coronary artery ligation, CCR1-MSCs accumulated in the infarcted myocardium at significantly higher levels than control-MSCs or CXCR2-MSCs 3 days postmyocardial infarction (MI). CCR1-MSC-injected hearts exhibited a significant reduction in infarct size, reduced cardiomyocytes apoptosis and increased capillary density in injured myocardium 3 days after MI. Furthermore, intramyocardial injection of CCR1-MSCs prevented cardiac remodeling and restored cardiac function 4 weeks after MI. CONCLUSIONS Our results demonstrate the in vitro and in vivo salutary effects of genetic modification of stem cells. Specifically, overexpression of chemokine receptor enhances the migration, survival and engraftment of MSCs, and may provide a new therapeutic strategy for the injured myocardium.
Collapse
Affiliation(s)
- Jing Huang
- Duke University Medical Center & Health System, DUMC 3701, Durham, NC 27701, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Walton SG, Lock EH, Ni A, Baraket M, Fernsler RF, Pappas DD, Strawhecker KE, Bujanda AA. Study of plasma-polyethylene interactions using electron beam-generated plasmas produced in Ar/SF6 mixtures. J Appl Polym Sci 2010. [DOI: 10.1002/app.32249] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
34
|
Kovesi T, Zaloum C, Stocco C, Fugler D, Dales RE, Ni A, Barrowman N, Gilbert NL, Miller JD. Heat recovery ventilators prevent respiratory disorders in Inuit children. Indoor Air 2009; 19:489-499. [PMID: 19719534 DOI: 10.1111/j.1600-0668.2009.00615.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
UNLABELLED Inuit infants have high rates of reported hospitalization for respiratory infection, associated with overcrowding and reduced ventilation. We performed a randomized, double-blind, placebo controlled trial to determine whether home heat recovery ventilators (HRV) would improve ventilation and reduce the risk of respiratory illnesses in young Inuit children. Inuit children under 6 years of age living in several communities in Nunavut, Canada were randomized to receive an active or placebo HRV. We monitored respiratory symptoms, health center encounters, and indoor air quality for 6 months. HRVs were placed in 68 homes, and 51 houses could be analyzed. Subjects had a mean age of 26.8 months. Active HRVs brought indoor carbon dioxide concentrations to within recommended concentrations. Relative humidity was also reduced. Use of HRV, compared with placebo, was associated with a progressive fall in the odds ratio for reported wheeze of 12.3% per week (95%CI 1.9-21.6%, P = 0.022). Rates of reported rhinitis were significantly lower in the HRV group than the placebo group in month 1 (odds ratio 0.20, 95%CI 0.058-0.69, P = 0.011) and in month 4 (odds ratio 0.24, 95%CI 0.054-0.90, P = 0.035). There were no significant reductions in the number of health center encounters, and there were no hospitalizations. Use of HRVs was associated with in improvement in air quality and reductions in reported respiratory symptoms in Inuit children. PRACTICAL IMPLICATIONS Reduced ventilation is common in the houses of Inuit children in arctic Canada, and is associated with an increased risk of respiratory infection. Installation of HRV brings indoor carbon dioxide concentration, as a marker of adequate ventilation, to within recommended concentrations, although relative humidity is also reduced. Installation of HRV is associated with improvements in indoor air quality, and a reduced risk of wheezing and rhinitis not associated with cold air exposure in young Inuit children. Further research is required to explore traditional Inuit cultural attitudes about air movement in dwellings.
Collapse
Affiliation(s)
- T Kovesi
- Department of Paediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Goel DP, Buckley R, deVries G, Abelseth G, Ni A, Gray R. Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial. ACTA ACUST UNITED AC 2009; 91:388-94. [PMID: 19258618 DOI: 10.1302/0301-620x.91b3.20820] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The incidence of deep-vein thrombosis and the need for thromboprophylaxis following isolated trauma below the knee is uncertain. We have investigated this with a prospective randomised double-blind controlled trial using low molecular weight heparin with saline injection as placebo in patients aged between 18 and 75 years who had sustained an isolated fracture below the knee which required operative fixation. All patients had surgery within 48 hours of injury and were randomised to receive either the placebo or low molecular weight heparin for 14 days, after which they underwent bilateral lower limb venography, interpreted by three independent radiologists. Further follow-up was undertaken at two, six, eight and 12 weeks. A total of 238 patients fulfilled all the inclusion criteria, with 127 in the low molecular weight heparin group and 111 in the placebo group, all of whom underwent bilateral venography. There was no statistically significant difference in the incidence of deep-vein thrombosis between those patients treated with low molecular weight heparin or the placebo (p = 0.22). The number of deep-vein thromboses in the two groups was 11 (8.7%) and 14 (12.6%), respectively. Age and the type of fracture were significantly associated with the rate of deep-vein thrombosis (p = 0.001 and p = 0.009, respectively) but gender, comorbidities and the body mass index were not. The overall incidence of deep-vein thrombosis in this series was 11%. There was no clinical or statistical significant reduction in the incidence of deep-vein thrombosis with the use of thromboprophylaxis. However, we accept that owing to a cessation of funding, recruitment to this trial had to be ended prior to establishing the necessary sample size. Our results cannot, therefore, categorically exclude the possibility that low molecular weight heparin treatment could be beneficial. We recommend a further multicentre trial be undertaken to resolve this matter.
Collapse
Affiliation(s)
- D P Goel
- Department of Orthopaedics, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada
| | | | | | | | | | | |
Collapse
|
36
|
Abstract
Animal and preliminary human studies of adult cell therapy following acute myocardial infarction have shown an overall improvement of cardiac function. Myocardial and vascular regeneration have been initially proposed as mechanisms of stem cell action. However, in many cases, the frequency of stem cell engraftment and the number of newly generated cardiomyocytes and vascular cells, either by transdifferentiation or cell fusion, appear too low to explain the significant cardiac improvement described. Accordingly, we and others have advanced an alternative hypothesis: the transplanted stem cells release soluble factors that, acting in a paracrine fashion, contribute to cardiac repair and regeneration. Indeed, cytokines and growth factors can induce cytoprotection and neovascularization. It has also been postulated that paracrine factors may mediate endogenous regeneration via activation of resident cardiac stem cells. Furthermore, cardiac remodeling, contractility, and metabolism may also be influenced in a paracrine fashion. This article reviews the potential paracrine mechanisms involved in adult stem cell signaling and therapy.
Collapse
Affiliation(s)
- Massimiliano Gnecchi
- Mandel Center for Hypertension Research, Duke University Medical Center, Durham, North Carolina 27710
- Division of Cardiology, Laboratory of Experimental Cardiology - Cell and Molecular Therapy, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
- Department of Heart, Blood and Lung, University of Pavia, 27100 Pavia, Italy
| | - Zhiping Zhang
- Mandel Center for Hypertension Research, Duke University Medical Center, Durham, North Carolina 27710
- Cardiovascular Division, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710
| | - Aiguo Ni
- Mandel Center for Hypertension Research, Duke University Medical Center, Durham, North Carolina 27710
- Cardiovascular Division, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710
| | - Victor J. Dzau
- Mandel Center for Hypertension Research, Duke University Medical Center, Durham, North Carolina 27710
- Cardiovascular Division, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710
| |
Collapse
|
37
|
Deb A, Davis BH, Guo J, Ni A, Huang J, Zhang Z, Mu H, Dzau VJ. SFRP2 regulates cardiomyogenic differentiation by inhibiting a positive transcriptional autofeedback loop of Wnt3a. Stem Cells 2007; 26:35-44. [PMID: 17916803 DOI: 10.1634/stemcells.2007-0475] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Wnts comprise a family of 20 lipid-modified glycoproteins in mammals and play critical roles during embryological development and organogenesis of several organ systems, including the heart. They are required for mesoderm formation and have been implicated in promoting cardiomyogenic differentiation of mammalian embryonic stem cells, but the underlying mechanisms regulating Wnt signaling during cardiomyogenesis remain poorly understood. In this report, we show that in a pluripotent mouse embryonal carcinoma stem cell line, SFRP2 inhibits cardiomyogenic differentiation by regulating Wnt3a transcription. SFRP2 inhibited early stages of cardiomyogenesis, preventing mesoderm specification and maintaining the cells in the undifferentiated state. Using a gain- and loss-of-function approach, we demonstrate that although addition of recombinant SFRP2 decreased Wnt3a transcription and cardiomyogenic differentiation, silencing of Sfrp2 led to enhanced Wnt3a transcription, mesoderm formation, and increased cardiomyogenesis. We show that the inhibitory effects of SFRP2 on Wnt transcription are secondary to interruption of a positive feedback effect of Wnt3a on its own transcription. Wnt3a increased its own transcription via the canonical pathway and TCF4 family of transcription factors, and the inhibitory effects of SFRP2 on Wnt3a transcription were associated with disruption of downstream canonical Wnt signaling. The inhibitory effects of Sfrp2 on Wnt3a expression identify Sfrp2 as a "checkpoint gene," which exerts its control on cardiomyogenesis through regulation of Wnt3a transcription.
Collapse
Affiliation(s)
- Arjun Deb
- Division of Cardiovascular Diseases and Mandel Center for Hypertension & Atherosclerosis Research, Department of Medicine, GSRB 2, Box 3178, Duke University Medical Center, Durham, North Carolina 27710, USA.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Ni A, Yin H, Agata J, Yang Z, Chao L, Chao J. Overexpression of kinin B1 receptors induces hypertensive response to des-Arg9-bradykinin and susceptibility to inflammation. J Biol Chem 2003; 278:219-25. [PMID: 12411434 DOI: 10.1074/jbc.m209490200] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We demonstrated that rat kinin B(1) receptors displayed a ligand-independent constitutive activity, assessed through inositol phosphate production in transiently or stably transfected human embryonic kidney 293A cells. Substitution of Ala for Asn(130) in the third transmembrane domain resulted in additional constitutive activation of the B(1) receptor. The constitutively active mutant N130A receptor could be further activated by the B(1) receptor agonist des-Arg(9)-bradykinin. To gain insights into the physiological function of the B(1) receptor, we have generated transgenic mice overexpressing wild-type and constitutively active mutant receptors under the control of human cytomegalovirus immediately early gene enhancer/promoter. The rat B(1) receptor transgene expression was detected in the aorta, brain, heart, lung, liver, kidney, uterus, and prostate of transgenic mice by reverse transcription-polymerase chain reaction/Southern blot analysis. Transgenic mice were fertile and normotensive. Overexpression of B(1) receptors exacerbated paw edema induced by carrageenan and rendered transgenic mice more susceptible to lipopolysaccharide-induced endotoxic shock. Interestingly, the hemodynamic response to kinins was altered in transgenic mice, with des-Arg(9)-bradykinin inducing blood pressure increase when intravenously administered. Our study supports an important role for B(1) receptors in modulating inflammatory responses and for the first time demonstrates that B(1) receptors mediate a hypertensive response to des-Arg(9)-bradykinin.
Collapse
Affiliation(s)
- Aiguo Ni
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
| | | | | | | | | | | |
Collapse
|
39
|
Emanueli C, Chao J, Regoli D, Chao L, Ni A, Madeddu P. The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. Br J Pharmacol 1999; 126:1769-76. [PMID: 10372819 PMCID: PMC1565971 DOI: 10.1038/sj.bjp.0702527] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/1998] [Revised: 01/13/1999] [Accepted: 02/10/1999] [Indexed: 11/09/2022] Open
Abstract
1. We evaluated if the brain bradykinin (BK) B1 receptor is involved in the regulation of blood pressure (BP) in conscious rats. 2. Basal mean BP and HR were 115 +/- 2 and 165 +/- 3 mmHg and 345 +/- 10 and 410 +/- 14 beats min in Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR), respectively. Intracerebroventricular (i.c.v.) injection of 1 nmol B1 receptor agonist Lys-desArg9-BK significantly increased the BP of WKY and SHR by 7+/-1 and 19+/-2 mmHg, respectively. One nmol Sar[D-Phe8]-desArg9-BK, a kininase-resistant B1 agonist, increased the BP of WKY and SHR by 19+/-2 and 17+/-2 mmHg, respectively and reduced HR in both strains. 3. I.c.v. injection of 0.01 nmol B1 antagonists, LysLeu8-desArg9-BK or AcLys[D-betaNal7,Ile8]-desArg9-BK (R715), significantly decreased mean BP in SHR (by 9+/-2 mmHg the former and 14+/-3 mmHg the latter compound), but not in WKY. In SHR, the BP response to R715 was associated to tachycardia. 4. I.c.v. Captopril, a kininase inhibitor, increased the BP of SHR, this response being partially prevented by i.c.v. R715 and reversed into a vasodepressor effect by R715 in combination with the B2 antagonist Icatibant. 5. I.c.v. antisense oligodeoxynucleotides (ODNs) targeted to the B1 receptor mRNA decreased BP in SHR, but not in WKY. HR was not altered in either strain. Distribution of fluorescein-conjugated ODNs was detected in brain areas surrounding cerebral ventricles. 6. Our results indicate that the brain B1 receptor participates in the regulation of BP. Activation of the B1 receptor by kinin metabolites could participate in the pathogenesis of hypertension in SHR.
Collapse
Affiliation(s)
- Costanza Emanueli
- Laboratorio di Patologia Vascolare, Istituto Dermopatico dell'Immacolata (IDI), Rome, Italy
- National Laboratory of the National Institute of Biostructures and Biosystems, Osilo, Italy
| | - Julie Chao
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, U.S.A
| | - Domenico Regoli
- Department of Pharmacology, Sherbrooke Medical University, Canada
| | - Lee Chao
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, U.S.A
| | - Aiguo Ni
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, U.S.A
| | - Paolo Madeddu
- Laboratorio di Patologia Vascolare, Istituto Dermopatico dell'Immacolata (IDI), Rome, Italy
- National Laboratory of the National Institute of Biostructures and Biosystems, Osilo, Italy
- Clinica Medica, University of Sassari, Italy
| |
Collapse
|
40
|
Abstract
The gene encoding rat bradykinin B1 receptor has been cloned by using a partial rat B1 cDNA probe. The rat B1 receptor gene contains two exons and the entire coding region is within the second exon. The 5'-flanking region of the rat B1 receptor gene contains several putative transcriptional regulatory sites including TATA box, cAMP response element, NF-kappaB and AP-1. It showed promoter activity inducible by lipopolysaccharide in vascular smooth muscle cells. Rat B1 receptor mRNA was found to be alternatively spliced and induced by lipopolysaccharide treatment in a wide range of tissues, such as the salivary gland, testis, kidney, lung, heart, prostate and aorta. The deduced rat B1 receptor amino acid sequence is 71% homologous to human and rabbit counterparts, and 89% homologous to the mouse counterpart. The expressed B1 receptor in HEK293 cells displayed a rank order of affinity for the kinin peptides: des-Arg9-BK>Lys-des-Arg9-BK approximately des-Arg9, Leu8-BK>Sar-Tyr-epsilonAhx-Lys-[D-betaNal7, Ile8]-des-Arg9-BK>Sar-Tyr-epsilonAhx-Lys-des-Arg9-BK>>BK>> Hoe140. These results indicate that the cloned gene encodes a functional rat B1 receptor.
Collapse
Affiliation(s)
- A Ni
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA
| | | | | | | |
Collapse
|
41
|
Ni A, Chao L, Chao J. Transcription factor nuclear factor kappaB regulates the inducible expression of the human B1 receptor gene in inflammation. J Biol Chem 1998; 273:2784-91. [PMID: 9446586 DOI: 10.1074/jbc.273.5.2784] [Citation(s) in RCA: 115] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Expression of the bradykinin B1 receptor gene is up-regulated in vascular smooth muscle cells (VSMCs) in response to a variety of inflammatory stimuli. We isolated the 5'-flanking region of the human bradykinin B1 receptor gene and examined its promoter activity by transient transfection analysis. This region (-2582 to +34) showed promoter activity inducible by lipopolysaccharide (LPS), tumor necrosis factor alpha (TNF-alpha), and interleukin-1beta (IL-1beta) in VSMCs. Further deletion analysis revealed that constructs containing 111 base pairs of 5'-flanking sequence were sufficient for transcriptional induction. Mutagenesis of a nuclear factor kappaB (NF-kappaB)-like site at -64 to -55 abolished most of the LPS, TNF-alpha, and IL-1beta inducibility, whereas a mutation of a cyclic AMP response element at -50 to -43 markedly reduced the basal promoter activity, and a mutation of the activator protein 1 (AP-1) site at -78 to -72 had minimal effects. Nuclear extracts from LPS, TNF-alpha, and IL-1beta-treated VSMCs, IL-1beta-treated human hepatoma HepG2, and human lung fibroblast IMR-90 cells showed strong inducible binding activity to the NF-kappaB-like site by gel shift assays. These results demonstrated that NF-kappaB-like nuclear factor was involved in the inducible expression of the human bradykinin B1 receptor gene during inflammatory processes.
Collapse
MESH Headings
- Amino Acid Sequence
- Base Sequence
- Cloning, Molecular
- DNA Mutational Analysis
- Gene Expression Regulation
- Genes, Reporter
- Humans
- Inflammation
- Interleukin-1/pharmacology
- Lipopolysaccharides/pharmacology
- Molecular Sequence Data
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/metabolism
- Mutagenesis, Site-Directed
- NF-kappa B/metabolism
- Promoter Regions, Genetic
- Protein Binding
- Receptor, Bradykinin B1
- Receptors, Bradykinin/biosynthesis
- Receptors, Bradykinin/genetics
- Tumor Necrosis Factor-alpha/pharmacology
Collapse
Affiliation(s)
- A Ni
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
| | | | | |
Collapse
|
42
|
Abstract
We have previously purified and cloned human kallistatin and rat kallikrein-binding protein (RKBP), which are tissue kallikrein inhibitors belonging to the serine proteinase inhibitor superfamily. In this study, we have cloned and sequenced the gene encoding rat kallistatin with Phe-Phe-Ser-Ala-Gln at positions P2-P3', which is identical to the reactive center of human kallistatin. Rat kallistatin is highly similar to human kallistatin, sharing 68% and 57% sequence identity at the cDNA and the amino acid levels. The rat kallistatin gene exists in a single copy and is located on chromosome 6. An SphI RFLP is found between SHR and WKY rats at or near the rat kallistatin gene locus. Two amino acid polymorphisms of the rat kallistatin gene between these two strains were found by sequence analysis. A candidate promoter in the 5'-flanking region (109 bp) of the rat kallistatin gene has been identified by reporter assays. The expression of rat kallistatin in the liver is growth-dependent and down-regulated during acute phase inflammation. Recombinant rat kallistatin produced in E. coli is able to bind to tissue kallikrein, and the interaction is inhibited by heparin. These characteristics define rat kallistatin as the counterpart of human kallistatin.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Base Sequence
- Carrier Proteins/genetics
- Carrier Proteins/metabolism
- Chromosome Mapping
- Cloning, Molecular
- DNA, Complementary/genetics
- Escherichia coli/genetics
- Gene Dosage
- Gene Expression Regulation, Developmental/physiology
- Genes/genetics
- Kallikreins/metabolism
- Liver/chemistry
- Molecular Sequence Data
- Point Mutation/genetics
- Polymorphism, Restriction Fragment Length
- Promoter Regions, Genetic/genetics
- RNA, Messenger/analysis
- Rats
- Rats, Inbred Strains
- Recombinant Fusion Proteins/metabolism
- Restriction Mapping
- Sequence Analysis, DNA
- Sequence Homology, Amino Acid
- Sequence Homology, Nucleic Acid
- Serpins/genetics
- Serpins/metabolism
Collapse
Affiliation(s)
- K X Chai
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425-2211, USA
| | | | | | | | | | | | | |
Collapse
|
43
|
Chai KX, Ni A, Wang D, Ward DC, Chao J, Chao L. Genomic DNA sequence, expression, and chromosomal localization of the human B1 bradykinin receptor gene BDKRB1. Genomics 1996; 31:51-7. [PMID: 8808279 DOI: 10.1006/geno.1996.0008] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We have cloned and sequenced the human B1 bradykinin receptor gene (BDKRB1), which contains an uninterrupted coding exon. A putative promoter was identified by linking various lengths of the 5'-flanking region of the B1 receptor gene coding sequence to a CAT reporter and assaying for CAT activity. Deletion analysis showed that a 300-bp fragment in the promoter region is sufficient to direct the synthesis of the reporter and that an enhancer-like element is present between -1842 and -812. A genomic Southern blot using the B1 cDNA revealed that the receptor is encoded by a single-copy gene. The gene is located on chromosome 14q32.1-q32.2, in close proximity to the B2 receptor gene. Northern blot analysis identified a 1.7- to 1.8-kb mature mRNA transcript of the B1 receptor gene in the kidney and pancreas. A widespread tissue distribution of the B1 gene expression was identified by RT-PCR-Southern blot analysis using specific oligonucleotide probes.
Collapse
MESH Headings
- Chloramphenicol O-Acetyltransferase/genetics
- Chromosome Mapping
- Chromosomes, Human, Pair 14/genetics
- Cloning, Molecular
- DNA, Complementary/genetics
- Enhancer Elements, Genetic
- Exons
- Gene Expression
- Genes, Reporter
- Humans
- In Situ Hybridization, Fluorescence
- Kidney/metabolism
- Pancreas/metabolism
- Polymerase Chain Reaction
- Promoter Regions, Genetic
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptor, Bradykinin B1
- Receptor, Bradykinin B2
- Receptors, Bradykinin/genetics
- Sequence Deletion
- Tissue Distribution
Collapse
Affiliation(s)
- K X Chai
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425, USA
| | | | | | | | | | | |
Collapse
|
44
|
Ni A, Everson S, Li Y, Ward ME. [Species-specific monoclonal antibodies against the major outer membrane protein (MOMP) of Chlamydia trachomatis]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1995; 17:428-33. [PMID: 9208568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The synthesized one quarter N-terminal MOMP of C. trachomatis was used for primary immunization of three male BALB/c mice (8 weeks of age), and the boost with C. trachomatis L1/440/Bu elementary bodies (EBs) was followed on day 14. Spleen cells from one mouse with good response of immunization were fused with murine myeloma NS-1 cells on day 24. The hybrid cell suspension was seeded into the wells of 96-well microtest plates which contained macrophage feeder layers. Anti-chlamydial antibodies in culture fluids were screened by ELISA with 1/4 MOMP & L1 EBs coated 96-well trays. Positive wells were cloned by limiting dilution. Four clones which secreted immunoglobulin G1 & G2a class were obtained after elimination of those clones that produced antibodies to C. psittaci strain EAE, C. pneumoniae strain ATCC VR1310 and uninfected BGMK cells. In micro-IF test, we found that the all four clones of MAbs reacted with our laboratory prepared L1, L2, A, B, C, E EBs, L2 tissue culture inclusions, as well as the EBs of all 15 standard serovars of C. trachomatis. The titers of their ascites were more than 1:12,800 in micro-IF test. It was shown that the four clones of MAbs reacted predominantly with 40,000 MOMP of C. trachomatis L1 in Western blot.
Collapse
Affiliation(s)
- A Ni
- PUMC Hospital, CAMS, Beijing
| | | | | | | |
Collapse
|
45
|
Ni A, Wang H, Dong P. [Chlamydia pneumoniae infection in patients with pneumonia, bronchitis and acute upper respiratory tract infection in Beijing]. Zhonghua Nei Ke Za Zhi 1995; 34:388-91. [PMID: 8582186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
A prospective study for C. pneumoniae infection was conducted in 134 patients with acute respiratory disease and 134 matched patients with other medical reasons from January to May 1994 in Beijing. The positive rate of micro-IF (MIF) IgG antibodies was 93% (125/134) and 89% (119/134) respectively (0.1 < P < 0.25) and the geometric mean titers (GMT) were not found to be significant (55.9 +/- 4.2 vs 41.7 +/- 2.8, 0.1 < P < 0.20). Ten patients, four (4/30) with pneumonia and six (6/81) with bronchitis were serologically diagnosed as having recent C. pneumoniae infection. Chronic bronchitis was statistically more frequent in patients with C. pneumoniae infection than those without (0.025 < P < 0.05). Patients with chronic bronchitis (GMT, 87.1 +/- 3.9; n = 36) tended to have higher IgG titers than those without (GMT, 47.6 +/- 4.1; n = 98, 0.02 < P < 0.05). Culture of retro-pharyngeal swab specimens for C. pneumoniae was negative in the all 134 studied patients.
Collapse
Affiliation(s)
- A Ni
- Department of Clinical Laboratories, Peking Union Medical College Hospital, Beijing
| | | | | |
Collapse
|
46
|
Abstract
The 26-residue peptide melittin present in bee venom has been shown to bind calmodulin tightly. In this study we synthesized the following series of deletion peptides of melittin by the solid-phase method: Mel12, Mel13, Mel14, Mel15, Mel15F. The results of this study show that the deletion peptides Mel14 and Mel15 have almost the same binding activity as the intact native peptide. Each deletion peptide forms a 1:1 complex with calmodulin according to electrophoresis analysis. When the tryptophanyl residue of Mel15 was replaced by the phenylalaninyl residue, the dissociation constant of the peptide-calmodulin complex increased. This shows the importance of the tryptophanyl residue for binding to calmodulin.
Collapse
Affiliation(s)
- L Liu
- Institute of Polymer Chemistry, Nankai University, Tianjin, China
| | | | | | | | | |
Collapse
|
47
|
Yan H, Cheng X, Ni A, He B. Resolution of Amino Acid Enantiomers by Ligand Exchange Chromatography on a New Chiral Packing. ACTA ACUST UNITED AC 1993. [DOI: 10.1080/10826079308019570] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|